Company / Cash & Equivalents
Amgen Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.1B
FY2025
5-year range
$7.6B / $12.0B
FY2021-FY2025
Trend
-23.8%
vs FY2024
Sector context
#4 of 209
Health Care
What the data says
Among 209 Health Care companies, Amgen is in the top 2% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $3.2B in FY2016 to $12.0B in FY2024.
Based on SEC 10-K filings.
$9.1B in FY2025 with a 5-year CAGR of +7.8%. Top quartile in the Health Care sector.
Declined from $10.9B to $9.1B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.2%
- 5-Year CAGR
- +7.8%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 209This company $9.1B Sector average $696.0M
▼
+1211.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 23.8% year-over-year.
- Ranks #4 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.1B | -23.8% |
| FY2024 | $12.0B | +9.4% |
| FY2023 | $10.9B | +43.5% |
| FY2022 | $7.6B | -4.5% |
| FY2021 | $8.0B | +27.5% |
| FY2020 | $6.3B | +3.8% |
| FY2019 | $6.0B | -13.1% |
| FY2018 | $6.9B | +82.8% |
| FY2017 | $3.8B | +17.2% |
| FY2016 | $3.2B | -21.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026